BIO3 Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.60 |
| 52 Week High | €32.20 |
| 52 Week Low | €25.20 |
| Beta | 0.26 |
| 1 Month Change | 9.16% |
| 3 Month Change | -3.38% |
| 1 Year Change | -7.14% |
| 3 Year Change | -2.39% |
| 5 Year Change | 29.12% |
| Change since IPO | 22.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -0.7% | -3.0% | -0.6% |
| 1Y | -7.1% | -12.4% | 1.8% |
Return vs Industry: BIO3 exceeded the Austrian Biotechs industry which returned -12.4% over the past year.
Return vs Market: BIO3 underperformed the Austrian Market which returned 1.8% over the past year.
Price Volatility
| BIO3 volatility | |
|---|---|
| BIO3 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.4% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: BIO3 has not had significant price volatility in the past 3 months.
Volatility Over Time: BIO3's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,426 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3 fundamental statistics | |
|---|---|
| Market cap | €1.39b |
| Earnings (TTM) | €127.00m |
| Revenue (TTM) | €684.60m |
8.9x
P/E Ratio1.7x
P/S RatioIs BIO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3 income statement (TTM) | |
|---|---|
| Revenue | €684.60m |
| Cost of Revenue | €404.30m |
| Gross Profit | €280.30m |
| Other Expenses | €153.30m |
| Earnings | €127.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 3.21 |
| Gross Margin | 40.94% |
| Net Profit Margin | 18.55% |
| Debt/Equity Ratio | 126.7% |
How did BIO3 perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield1%
Payout RatioDoes BIO3 pay a reliable dividends?
See BIO3 dividend history and benchmarks| Biotest dividend dates | |
|---|---|
| Ex Dividend Date | May 08 2024 |
| Dividend Pay Date | May 13 2024 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 24 days |
Does BIO3 pay a reliable dividends?
See BIO3 dividend history and benchmarks